TNFSF11 and infection: Specifically, several adverse effects have been reported with the use of Denosumab [11] (a fully human monoclonal antibody that inhibits the receptor activator of the nuclear factor kappa-B ligand (RANKL)), including serious infections [12], osteonecrosis of the jaw [13], and atypical femur fracture [14].